Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Corey

Showing results (121-130 of 222) with videos related to

Pageof 23
Sort By:
Cell Reports|May 28, 2020
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication StressMichael D Nyquist, Alexandra Corella, Ilsa Coleman, et al.
Scientific Reports|February 26, 2021
A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid cultureElise Y Cai, Jose Garcia, Yuzhen Liu, et al.
International Journal of Oncology|January 31, 2015
CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cellsNobuyuki Ishikura, Hiromitsu Kawata, Ayako Nishimoto, et al.
Neoplasia (New York, N.Y.)|March 15, 2025
LSD1+8a is an RNA biomarker of neuroendocrine prostate cancerAnbarasu Kumaraswamy, Rahul Mannan, Olivia A Swaim, et al.
The Prostate|February 4, 2017
LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer TherapeuticsHolly M Nguyen, Robert L Vessella, Colm Morrissey, et al.
Communications Medicine|September 26, 2022
Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomesShu Ning, Jinge Zhao, Alan P Lombard, et al.
Nature Communications|September 26, 2014
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancerColin C Pritchard, Colm Morrissey, Akash Kumar, et al.
Cell Reports|September 11, 2025
Disrupting the interaction between androgen receptor and its coregulator WDR77 delays the growth of treatment-resistant prostate cancerUjjwal R Dahiya, Sangeeta Kumari, Nidhi Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2018
A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic ScreeningMichael L Beshiri, Caitlin M Tice, Crystal Tran, et al.
The Journal of Clinical Investigation|July 17, 2019
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damagePayel Chatterjee, Michael T Schweizer, Jared M Lucas, et al.
Pageof 23

Showing results (121-130 of 222) with videos related to

Sort By:
Pageof 23
Cell Reports|May 28, 2020
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication StressMichael D Nyquist, Alexandra Corella, Ilsa Coleman, et al.
Scientific Reports|February 26, 2021
A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid cultureElise Y Cai, Jose Garcia, Yuzhen Liu, et al.
International Journal of Oncology|January 31, 2015
CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cellsNobuyuki Ishikura, Hiromitsu Kawata, Ayako Nishimoto, et al.
Neoplasia (New York, N.Y.)|March 15, 2025
LSD1+8a is an RNA biomarker of neuroendocrine prostate cancerAnbarasu Kumaraswamy, Rahul Mannan, Olivia A Swaim, et al.
The Prostate|February 4, 2017
LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer TherapeuticsHolly M Nguyen, Robert L Vessella, Colm Morrissey, et al.
Communications Medicine|September 26, 2022
Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomesShu Ning, Jinge Zhao, Alan P Lombard, et al.
Nature Communications|September 26, 2014
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancerColin C Pritchard, Colm Morrissey, Akash Kumar, et al.
Cell Reports|September 11, 2025
Disrupting the interaction between androgen receptor and its coregulator WDR77 delays the growth of treatment-resistant prostate cancerUjjwal R Dahiya, Sangeeta Kumari, Nidhi Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2018
A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic ScreeningMichael L Beshiri, Caitlin M Tice, Crystal Tran, et al.
The Journal of Clinical Investigation|July 17, 2019
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damagePayel Chatterjee, Michael T Schweizer, Jared M Lucas, et al.
Pageof 23